335 related articles for article (PubMed ID: 10099565)
21. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin.
Waurzyniak B; Schneider EA; Tumer N; Yanishevski Y; Gunther R; Chelstrom LM; Wendorf H; Myers DE; Irvin JD; Messinger Y; Ek O; Zeren T; Langlie MC; Evans WE; Uckun FM
Clin Cancer Res; 1997 Jun; 3(6):881-90. PubMed ID: 9815763
[TBL] [Abstract][Full Text] [Related]
22. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
[TBL] [Abstract][Full Text] [Related]
23. Treatment of solid tumors with immunotoxins.
Messmer D; Kipps TJ
Breast Cancer Res; 2005; 7(5):184-6. PubMed ID: 16168135
[TBL] [Abstract][Full Text] [Related]
24. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
25. Selective inhibition of growing pigment epithelial cells by a receptor-directed immunotoxin.
Davis AA; Whidby DE; Privette T; Houston LL; Hunt RC
Invest Ophthalmol Vis Sci; 1990 Dec; 31(12):2514-9. PubMed ID: 2265991
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys.
Uckun FM; Yanishevski Y; Tumer N; Waurzyniak B; Messinger Y; Chelstrom LM; Lisowski EA; Ek O; Zeren T; Wendorf H; Langlie MC; Irvin JD; Myers DE; Fuller GB; Evans W; Gunther R
Clin Cancer Res; 1997 Mar; 3(3):325-37. PubMed ID: 9815689
[TBL] [Abstract][Full Text] [Related]
27. Immunological and biological stability of immunotoxins in vivo as studied by the clearance of disulfide-linked pokeweed antiviral protein-antibody conjugates from blood.
Ramakrishnan S; Houston LL
Cancer Res; 1985 May; 45(5):2031-6. PubMed ID: 3986759
[TBL] [Abstract][Full Text] [Related]
28. Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells.
Rosenblum MG; Cheung L; Kim SK; Mujoo K; Donato NJ; Murray JL
Cancer Immunol Immunother; 1996 Feb; 42(2):115-21. PubMed ID: 8620520
[TBL] [Abstract][Full Text] [Related]
29. An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins.
Tazzari PL; de Totero D; Bolognesi A; Testoni N; Pileri S; Roncella S; Reato G; Stein H; Gobbi M; Stirpe F
Haematologica; 1999 Nov; 84(11):988-95. PubMed ID: 10553158
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin.
Mujoo K; Cheung L; Murray JL; Rosenblum MG
Cancer Immunol Immunother; 1995 May; 40(5):339-45. PubMed ID: 7600567
[TBL] [Abstract][Full Text] [Related]
31. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.
Flavell DJ; Warnes SL; Noss AL; Flavell SU
Br J Cancer; 2000 Dec; 83(12):1755-61. PubMed ID: 11104577
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxicity of gelonin and its conjugates with antibodies is determined by the extent of their endocytosis.
Goldmacher VS; Scott CF; Lambert JM; McIntyre GD; Blättler WA; Collnhson AR; Stewart JK; Chong LD; Cook S; Slayter HS
J Cell Physiol; 1989 Oct; 141(1):222-34. PubMed ID: 2528553
[TBL] [Abstract][Full Text] [Related]
33. Immunotoxins to the murine transferrin receptor: intracavitary therapy of mice bearing syngeneic peritoneal tumors.
Bjorn MJ; Groetsema G
Cancer Res; 1987 Dec; 47(24 Pt 1):6639-45. PubMed ID: 3499979
[TBL] [Abstract][Full Text] [Related]
34. Wortmannin, a phosphoinositide 3-kinase inhibitor, selectively enhances cytotoxicity of receptor-directed-toxin chimeras in vitro and in vivo.
Davol PA; Bizuneh A; Frackelton AR
Anticancer Res; 1999; 19(3A):1705-13. PubMed ID: 10470104
[TBL] [Abstract][Full Text] [Related]
35. Shock wave permeabilization with ribosome inactivating proteins: a new approach to tumor therapy.
Delius M; Adams G
Cancer Res; 1999 Oct; 59(20):5227-32. PubMed ID: 10537301
[TBL] [Abstract][Full Text] [Related]
36. Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107.
Hagihara N; Walbridge S; Olson AW; Oldfield EH; Youle RJ
Cancer Res; 2000 Jan; 60(2):230-4. PubMed ID: 10667564
[TBL] [Abstract][Full Text] [Related]
37. Mutations in diphtheria toxin to improve immunotoxin selectivity and understand toxin entry into cells.
Youle RJ
Semin Cell Biol; 1991 Feb; 2(1):39-45. PubMed ID: 1954342
[TBL] [Abstract][Full Text] [Related]
38. Use of blue-sepharose for purification of immunotoxin containing type 1 ribosome-inactivating protein, gelonin.
Masuda K; Hirano K; Takagishi Y
Biomed Chromatogr; 1994; 8(1):9-13. PubMed ID: 7510554
[TBL] [Abstract][Full Text] [Related]
39. Cytotoxicity of gelonin conjugated to targeting molecules: effects of weak amines, monensin, adenovirus, and adenoviral capsid proteins penton, hexon, and fiber.
Goldmacher VS; Blättler WA; Lambert JM; McIntyre G; Stewart J
Mol Pharmacol; 1989 Nov; 36(5):818-22. PubMed ID: 2531272
[TBL] [Abstract][Full Text] [Related]
40. Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin.
Cizeau J; Grenkow DM; Brown JG; Entwistle J; MacDonald GC
J Immunother; 2009; 32(6):574-84. PubMed ID: 19483652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
